Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Genome Biol. 2020 Dec 1;21(1):290. doi: 10.1186/s13059-020-02206-w.
One ongoing concern about CRISPR-Cas9 genome editing is that unspecific guide RNA (gRNA) binding may induce off-target mutations. However, accurate prediction of CRISPR-Cas9 off-target activity is challenging. Here, we present SMRT-OTS and Nano-OTS, two novel, amplification-free, long-read sequencing protocols for detection of gRNA-driven digestion of genomic DNA by Cas9 in vitro.
The methods are assessed using the human cell line HEK293, re-sequenced at 18x coverage using highly accurate HiFi SMRT reads. SMRT-OTS and Nano-OTS are first applied to three different gRNAs targeting HEK293 genomic DNA, resulting in a set of 55 high-confidence gRNA cleavage sites identified by both methods. Twenty-five of these sites are not reported by off-target prediction software, either because they contain four or more single nucleotide mismatches or insertion/deletion mismatches, as compared with the human reference. Additional experiments reveal that 85% of Cas9 cleavage sites are also found by other in vitro-based methods and that on- and off-target sites are detectable in gene bodies where short-reads fail to uniquely align. Even though SMRT-OTS and Nano-OTS identify several sites with previously validated off-target editing activity in cells, our own CRISPR-Cas9 editing experiments in human fibroblasts do not give rise to detectable off-target mutations at the in vitro-predicted sites. However, indel and structural variation events are enriched at the on-target sites.
Amplification-free long-read sequencing reveals Cas9 cleavage sites in vitro that would have been difficult to predict using computational tools, including in dark genomic regions inaccessible by short-read sequencing.
人们一直担心 CRISPR-Cas9 基因组编辑技术会引起非特异性向导 RNA(gRNA)结合诱导脱靶突变。然而,准确预测 CRISPR-Cas9 的脱靶活性具有挑战性。在这里,我们提出了 SMRT-OTS 和 Nano-OTS,这两种新的、无扩增、长读测序协议,用于检测 Cas9 在体外对基因组 DNA 的 gRNA 驱动消化。
该方法使用人类细胞系 HEK293 进行评估,使用高度准确的 HiFi SMRT 读数进行 18x 覆盖的重新测序。SMRT-OTS 和 Nano-OTS 首先应用于靶向 HEK293 基因组 DNA 的三种不同 gRNA,两种方法共鉴定出 55 个高置信度的 gRNA 切割位点。其中 25 个位点未被靶外预测软件报道,要么是因为它们与人类参考序列相比含有四个或更多的单核苷酸错配或插入/缺失错配,要么是因为它们位于基因体中,短读序列无法唯一比对。额外的实验表明,85%的 Cas9 切割位点也可通过其他体外方法检测到,并且在短读序列无法唯一比对的基因体中可以检测到靶内和靶外位点。尽管 SMRT-OTS 和 Nano-OTS 鉴定出了几个在细胞中具有先前验证的靶外编辑活性的位点,但我们自己在人类成纤维细胞中的 CRISPR-Cas9 编辑实验并没有在体外预测的位点产生可检测的靶外突变。然而,插入缺失和结构变异事件在靶内位点富集。
无扩增长读测序揭示了体外 Cas9 切割位点,这些位点很难通过计算工具预测,包括短读测序无法到达的暗基因组区域。